Fig. 7 | Signal Transduction and Targeted Therapy

Fig. 7

From: A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants

Fig. 7

RBDXBB.1.5-HR vaccine improves neutralizing activities in human participants. a A total of 54 participants in age from 21 to 71 with (n = 15) or without underlying diseases (n = 39) were recruited into the clinical investigator-initiated trial (IIT) to evaluate the immunogenicity of RBDXBB.1.5-HR vaccine after sequential booster vaccination. The plasma samples were collected on days 7, 14 and 28 for pseudovirus neutralization assay (n = 54 samples). b The neutralizing antibodies in sera collected on day 14 against authentic XBB.1.5 and EG.5.1 viruses (n = 54 samples). Data are presented as geometric mean values with SD

Back to article page